Content uniformity is the pharmacopoeial requirement, codified in USP <905> Uniformity of Dosage Units and EP 2.9.40, that the active ingredient content of individual dosage units (tablets, capsules, gummies, softgels, lozenges) fall within defined limits of label claim with stated statistical confidence. The standard uses one of two test approaches: weight variation (acceptable when the active is uniformly distributed and the unit weight is the primary variability source) or content uniformity by individual assay (required when active distribution within the matrix is variable, including most gummies, suspensions, low-dose actives, and inhalation products). The acceptance criterion is expressed as an Acceptance Value (AV) calculated from the mean, standard deviation and a reference value, with a first-stage limit of L1 = 15.0 and a second-stage limit of L2 = 25.0.

For dietary supplements under 21 CFR 111, content uniformity testing is required as part of finished-product release. The operational risk varies by dosage form: tablets and capsules with adequately blended powders typically pass with conventional sampling; gummies face depositor-driven variability across the mould plate and across the run (slurry segregation, hot-tank settling, depositor head accuracy), driving the need for in-process sampling at multiple time points and tightened release specifications; softgel suspensions face fill homogeneity variability driven by active particle size and settling in the fill tank; chewables and lozenges face blend uniformity issues with low-dose actives.

Defensible programmes specify the sampling plan in the master manufacturing record (number of units, sampling time points across the run, retention for re-test), trend the AV results across batches, link AV drift to depositor maintenance, slurry mixing parameters or particle size shifts, and require requalification of equipment after process changes. Under-specified sampling plans are a recurring 21 CFR 111 inspection finding; over-reliance on weight variation for dosage forms where active distribution is genuinely variable is another. The label dose, the upper specification limit and any regulatory upper-limit constraints (vitamin A, vitamin D in some jurisdictions) interact — a high overage strategy chosen to defend end-of-shelf-life label claim may push individual units above the release upper specification.

Regulatory anchors

USP <905>
EP 2.9.40
21 CFR 111.75

Industries that live with this

Dietary Supplements Pharmaceutical

How V5 handles it

From the first pull to a signed CoA in your customer's hands.

One connected QC loop. The analyst runs the sample on the kiosk; the result lands on the chart; an out-of-spec opens its own investigation, spawns a CAPA, holds the batch and routes the disposition; the released lot's Certificate of Analysis is built from real values, signed under §11.50, and delivered to the customer portal with every view logged. No spreadsheets. No retyping. No quiet edits.

QMS — quality engineered into every action, not bolted on.

Because V5 owns the operator action, the QMS sees the data the second it’s captured — not at the end of the shift.

Related terms

ICH Q1A Probiotic CFU